Shared on06 Sep 25
With both consensus revenue growth and net profit margin forecasts for Metropolis Healthcare remaining stable, analysts have left their fair value estimate unchanged at ₹2145. What's in the News Board meeting scheduled to consider and approve un-audited standalone and consolidated financial results for the quarter ended June 30, 2025, and to discuss other matters.
Shared on23 Apr 25Fair value Decreased 0.11%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Decreased 0.40%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Decreased 0.89%
AnalystConsensusTarget has increased revenue growth from 14.0% to 16.3%.
Shared on02 Apr 25Fair value Increased 0.88%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on13 Mar 25Fair value Increased 7.96%
AnalystConsensusTarget has decreased revenue growth from 17.7% to 13.2%.